Target intelligence / Profile preview

Solute carrier family 2, facilitated glucose transporter member 2 (GLUT2) (SLC2A2)

Target
SLC2A2
Molecular classification
Transporter, Major facilitator superfamily, Sugar transporter
01

Overview

Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2), commonly known as GLUT2, is a low-affinity, high-capacity transmembrane glycoprotein that mediates the bidirectional facilitated transport of glucose, fructose, and galactose across cell membranes. It is primarily expressed in key metabolic tissues, including hepatocytes, pancreatic beta cells, renal proximal tubules, and the basolateral membrane of intestinal epithelial cells, where it plays a pivotal role in maintaining systemic glucose homeostasis and acting as a glucose sensor. In pancreatic beta cells, GLUT2-mediated glucose uptake couples extracellular glucose levels to insulin secretion, while in hepatocytes, it regulates glucose uptake during feeding and glucose release during fasting.\n\nDysregulation or genetic mutations in SLC2A2 are strongly associated with metabolic disorders and malignancies. Biallelic loss-of-function mutations in SLC2A2 cause Fanconi-Bickel syndrome, a rare glycogen storage disease characterized by hepatorenal glycogen accumulation, renal tubular dysfunction, and severe dysglycemia. Furthermore, common polymorphisms in SLC2A2 are linked to type 2 diabetes susceptibility and can modulate patient responsiveness to antidiabetic therapies like metformin. In oncology, altered SLC2A2 expression is observed in cancers such as hepatocellular carcinoma and gastric cancer, where it supports the high metabolic demands of tumor cells, making it an attractive target for diagnostic, prognostic, and therapeutic interventions.

Other names
GLUT2GLUT-2Glucose transporter type 2Glucose transporter type 2, liverSolute carrier family 2 member 2
02

Mechanism of action

Drugs targeting SLC2A2 (GLUT2) act primarily by inhibiting its facilitative hexose transport activity, thereby blocking the cellular uptake of glucose or fructose. Some natural compounds and small molecules act as competitive or non-competitive inhibitors of GLUT2 to manage hyperglycemia or reduce cancer cell proliferation. Conversely, certain cytotoxic agents like streptozocin utilize GLUT2 as a portal for cellular entry to selectively destroy pancreatic beta cells. Additionally, some drugs indirectly modulate GLUT2 expression levels to restore glucose homeostasis.

03

Biological functions

Facilitated glucose transportBidirectional glucose transportGlucose sensingFructose transportGalactose transportRenal glucose reabsorptionIntestinal glucose absorption
04

Disease associations

Type 2 diabetes mellitusFanconi-Bickel syndromeHepatocellular carcinomaGastric cancerGlycogen storage diseaseObesity
05

Safety considerations

Impaired glucose homeostasisFasting hypoglycemiaPostprandial hyperglycemiaFanconi-Bickel syndrome-like symptomsRenal tubular dysfunction (glucosuria, phosphaturia, aminoaciduria)Glycogen accumulation in liver and kidneyAltered insulin secretion
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

SLC2A2 expression levelSLC2A2 mutation statusrs8192675 genotypeHbA1cFasting plasma glucoseUrinary retinol-binding protein (RBP)-creatinine ratioFractional excretion of phosphate (FE PO4)

Beyond the preview

Go deeper on Solute carrier family 2, facilitated glucose transporter member 2 (GLUT2) (SLC2A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 2 (GLUT2) (SLC2A2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call